In this issue of EBM, we have abstracted 2 new large trials of prostate cancer screening that come to opposite conclusions: one shows a just statistically significant (p = 0.04) reduction in prostate cancer death and the other suggests an increase. Much of the news headlines only seemed to pick up on one article or the other. However, the BBC news story quoted both the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the PLCO …